These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12841062)

  • 1. Assessing the impact of drug-eluting stents. Hospitals must be prepared to absorb a potentially negative financial impact.
    Pfeiffer H
    Healthc Exec; 2003; 18(4):60-1. PubMed ID: 12841062
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-eluting stent prices steady, usage declined over past several months.
    Hosp Mater Manage; 2007 Jun; 32(6):1, 5-8. PubMed ID: 17612009
    [No Abstract]   [Full Text] [Related]  

  • 3. Competition propping up. Second drug-eluting stent will be cheaper, plentiful.
    Becker C
    Mod Healthc; 2004 Mar; 34(11):12. PubMed ID: 15069793
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug-eluting stents.
    Rinfret S; Schampaert E
    CMAJ; 2007 May; 176(11):1611-2. PubMed ID: 17515589
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-eluting stents.
    Cohen DJ; Bakhai A
    CMAJ; 2007 May; 176(11):1612. PubMed ID: 17515592
    [No Abstract]   [Full Text] [Related]  

  • 6. Could your financial health be heading for heart break?
    Finarelli HJ
    Healthc Financ Manage; 2003 Aug; 57(8):68-72. PubMed ID: 12938623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigm shifts in cardiovascular medicine.
    Holmes DR; Firth BG; Wood DL
    J Am Coll Cardiol; 2004 Feb; 43(4):507-12. PubMed ID: 14975455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of drug-eluting stents on hospital systems: a disease-state model.
    Kong DF; Eisenstein EL; Sketch MH; Zidar JP; Ryan TJ; Harrington RA; Newman MF; Smith PK; Mark DB; Califf RM
    Am Heart J; 2004 Mar; 147(3):449-56. PubMed ID: 14999193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)?
    Berger PB; Sketch MH; Califf RM
    Circulation; 2004 Mar; 109(9):1079-81. PubMed ID: 15007018
    [No Abstract]   [Full Text] [Related]  

  • 10. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
    Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system.
    Ekman M; Sjögren I; James S
    Scand Cardiovasc J; 2006 Feb; 40(1):17-24. PubMed ID: 16448993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Welcome drop seen in stent prices.
    Hosp Mater Manage; 2006 Jul; 31(7):1, 5-6. PubMed ID: 16871664
    [No Abstract]   [Full Text] [Related]  

  • 14. Saving time, saving money: a time and motion study with contrast management systems.
    Lehmann C; Hotaling M
    J Invasive Cardiol; 2005 Feb; 17(2):118-21; quiz 122. PubMed ID: 15687541
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proactive approach to reimbursement in the era of drug-eluting stents.
    Richner R
    J Cardiovasc Manag; 2002; 13(5):32-3. PubMed ID: 12412361
    [No Abstract]   [Full Text] [Related]  

  • 17. Managing technological explosion in the medical management of coronary artery disease, Part II. DES economic modeling: budgeting strategies for drug-eluting stent technology.
    Chumer K; DeCerce J; Vaul J
    J Cardiovasc Manag; 2002; 13(4):16-20. PubMed ID: 12192774
    [No Abstract]   [Full Text] [Related]  

  • 18. Dollars and stents: is reimbursement floating out of reach?
    Rohland P
    J Cardiovasc Manag; 1999; 10(6):16-7. PubMed ID: 10662365
    [No Abstract]   [Full Text] [Related]  

  • 19. Medical/surgical advances. The unkindest cut.
    Haugh R
    Hosp Health Netw; 2002 Nov; 76(11):14, 16. PubMed ID: 12465578
    [No Abstract]   [Full Text] [Related]  

  • 20. Hard to curb overuse of drug-eluting stents.
    Pope T
    Manag Care; 2006 Jun; 15(6):48, 51, 53. PubMed ID: 16838885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.